Magenta Therapeutics Analyst Ratings
Magenta Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/21/2022 | 664.33% | BTIG | $6 → $3 | Maintains | Buy |
| 08/25/2022 | 409.55% | Goldman Sachs | → $2 | Downgrades | Buy → Neutral |
| 05/24/2022 | 409.55% | Goldman Sachs | $3 → $2 | Maintains | Buy |
| 04/18/2022 | 1428.66% | BTIG | $10 → $6 | Maintains | Buy |
| 04/18/2022 | 1938.22% | Mizuho | $17 → $8 | Maintains | Buy |
| 01/24/2022 | 1428.66% | B. Riley Securities | $13 → $6 | Maintains | Buy |
| 01/06/2022 | 1938.22% | Goldman Sachs | $7 → $8 | Upgrades | Neutral → Buy |
| 08/03/2021 | 1683.44% | JP Morgan | $16 → $7 | Downgrades | Overweight → Neutral |
| 06/29/2021 | 4995.54% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 4995.54% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/18/2021 | 5250.32% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 01/07/2021 | 3976.43% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/08/2020 | 3721.66% | Goldman Sachs | → $15 | Upgrades | Neutral → Buy |
| 12/06/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/06/2019 | 4485.99% | Goldman Sachs | → $18 | Assumes | → Neutral |
| 03/25/2019 | 3976.43% | Goldman Sachs | $17 → $16 | Downgrades | Buy → Neutral |
| 03/15/2019 | — | Raymond James | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 4485.99% | Goldman Sachs | → $18 | Initiates Coverage On | → Buy |
| 07/16/2018 | 4485.99% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 5505.1% | Wedbush | → $22 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/21/2022 | 664.33% | BTIG | $6 → $3 | 維護 | 買 |
| 08/25/2022 | 409.55% | 高盛 | → $2 | 評級下調 | 購買→中性 |
| 05/24/2022 | 409.55% | 高盛 | $3 → $2 | 維護 | 買 |
| 04/18/2022 | 1428.66% | BTIG | $10 → $6 | 維護 | 買 |
| 04/18/2022 | 1938.22% | 瑞穗 | $17 → $8 | 維護 | 買 |
| 01/24/2022 | 1428.66% | B.萊利證券 | $13 → $6 | 維護 | 買 |
| 01/06/2022 | 1938.22% | 高盛 | $7 → $8 | 升級 | 中性→購買 |
| 08/03/2021 | 1683.44% | 摩根大通 | $16 → $7 | 評級下調 | 超重→中性 |
| 06/29/2021 | 4995.54% | 康託·菲茨傑拉德 | → $20 | 開始承保 | →超重 |
| 06/15/2021 | 4995.54% | BTIG | → $20 | 開始承保 | →購買 |
| 05/18/2021 | 5250.32% | B.萊利證券 | → $21 | 開始承保 | →購買 |
| 01/07/2021 | 3976.43% | 瑞穗 | → $16 | 開始承保 | →購買 |
| 06/08/2020 | 3721.66% | 高盛 | → $15 | 升級 | 中性→購買 |
| 12/06/2019 | — | BTIG | 開始承保 | →購買 | |
| 12/06/2019 | 4485.99% | 高盛 | → $18 | 假設 | →中性 |
| 03/25/2019 | 3976.43% | 高盛 | $17 → $16 | 評級下調 | 購買→中性 |
| 03/15/2019 | — | 雷蒙德·詹姆斯 | 開始承保 | →跑贏大盤 | |
| 07/16/2018 | 4485.99% | 高盛 | → $18 | 開始承保 | →購買 |
| 07/16/2018 | 4485.99% | 摩根大通 | → $18 | 開始承保 | →超重 |
| 07/16/2018 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 07/16/2018 | 5505.1% | 韋德布什 | → $22 | 開始承保 | →跑贏大盤 |
What is the target price for Magenta Therapeutics (MGTA)?
品紅治療公司(MGTA)的目標價格是多少？
The latest price target for Magenta Therapeutics (NASDAQ: MGTA) was reported by BTIG on December 21, 2022. The analyst firm set a price target for $3.00 expecting MGTA to rise to within 12 months (a possible 664.33% upside). 7 analyst firms have reported ratings in the last year.
品紅治療公司(納斯達克：MGTA)的最新目標價是由BTIG於2022年12月21日報道的。這家分析公司將目標價定為3美元，預計MGTA將在12個月內上漲至(可能上漲664.33%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Magenta Therapeutics (MGTA)?
洋紅色治療公司(MGTA)的最新分析師評級是多少？
The latest analyst rating for Magenta Therapeutics (NASDAQ: MGTA) was provided by BTIG, and Magenta Therapeutics maintained their buy rating.
納斯達克集團提供了對品紅治療公司(股票代碼：MGTA)的最新分析師評級，品紅治療公司維持了買入評級。
When is the next analyst rating going to be posted or updated for Magenta Therapeutics (MGTA)?
Magenta治療公司(MGTA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Magenta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Magenta Therapeutics was filed on December 21, 2022 so you should expect the next rating to be made available sometime around December 21, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與洋紅治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Magenta治療公司的上一次評級是在2022年12月21日提交的，所以你應該預計下一次評級將在2023年12月21日左右提供。
Is the Analyst Rating Magenta Therapeutics (MGTA) correct?
分析師對洋紅治療公司(MGTA)的評級正確嗎？
While ratings are subjective and will change, the latest Magenta Therapeutics (MGTA) rating was a maintained with a price target of $6.00 to $3.00. The current price Magenta Therapeutics (MGTA) is trading at is $0.39, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的洋紅治療公司(MGTA)評級保持不變，目標價在6.00美元至3.00美元之間。目前洋紅色治療公司(MGTA)的交易價格為0.39美元，超出了分析師的預測範圍。